NCT05153889

Brief Summary

Favourable in-hospital outcome is observed in numerous patients after Non ST myocardial infarction (NSTEMI) with invasive strategy but European guidelines proposed systematic intensive care unit monitoring up to 24 h in lower risk patients (grade 1, level of evidence C). Regarding absence of prospective study supporting this strategy, we assessed the hypothesis that the lower risk NSTEMI patients identified through simple medical criteria and after coronary angiography evaluation may not require intensive care unit admission.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 10, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

December 18, 2021

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

January 17, 2024

Status Verified

January 1, 2024

Enrollment Period

3.5 years

First QC Date

October 27, 2021

Last Update Submit

January 15, 2024

Conditions

Keywords

Intensive Care Unit; General Cardiology Ward; ECG monitoring; Low risk NSTEMI

Outcome Measures

Primary Outcomes (1)

  • Success of the experimental strategy defined by absence of major adverse events 4 +/- 3 days after inclusion

    Major adverse events include : mortality (total and cardiovascular), severe bleeding (BARC criteria \>2), major vascular events (BARC 3 or 4 criteria) , cardiac failure requiring specific therapy ,acute kidney injury (RAKIN classification ≥grade 2) , major neurologic events confirmed with brain imaging, severe conductive or rhythm disorder, new coronary ischemic event requiring coronary angiography, any medical decision for secondary ICU transfer

    4 +/- 3 days after inclusion

Secondary Outcomes (9)

  • Incidence of low vs high risk NSTEMI patients admitted in ICU or in cath lab

    1 month follow up

  • Incidence of each event included in the combined primary outcome

    1 month follow up

  • Comparison of hospitalization length of stay for the 2 groups

    though hospital follow up, an average of 5 days

  • ICU length of stay in the control group

    though hospital follow up, an average of 5 days

  • Evolution of patient satisfaction (questionnaire)

    1 month +/- 7 days after inclusion

  • +4 more secondary outcomes

Study Arms (2)

Intensive care unit

OTHER

systematic intensive care unit (ICU) monitoring

Other: Hospitalized in Intensive care unit

General cardiology ward

EXPERIMENTAL

Group without ECG monitoring

Other: Hospitalized in General cardiology ward

Interventions

Patient hospitalized in Intensive care unit with ECG monitoring

Intensive care unit

Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.

General cardiology ward

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> or = to 18 years
  • NSTEMI was defined according guidelines with chest pain with or without ECG modifications and significant troponin elevation (hs-cTn T \*≥ 52 ng/l) or significant variation \> 10 ng/l between 2 dosages between 1 or 3 hours interval) \* Elecsys Roche
  • Coronary angiography mandatory \< 24 h after first troponin assay according to 2020 NSTEMI guidelines and PCI if required
  • Low risk NSTEMI defined with (all necessary):
  • Age\<85 years
  • Optimal antithrombotic therapy using new generation P2Y12 inhibitors (ticagrelor or prasugrel) or clopidogrel and aspirin with preloading at the latest before PCI
  • Success of PCI (one or 2 arteries)
  • Low risk of severe arrhythmia (ESC criteria) if none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF \<40%, failed reperfusion, additional critical coronary stenosis of major vessels, complications related to percutaneous revascularization,
  • No major comorbidities requiring specific care
  • Success of PCI without any event within 30 minutes after the procedure
  • Low bleeding risk (ESC criteria) according to CRUSADE criteria validated in NSTEMI

You may not qualify if:

  • STEMI
  • Unstable angina troponin \<5ng/l\* or \<14ng/l with variation \<4ng/l between 2 dosages )\* Elecsys Roche
  • High risk NSTEMI if one low risk criteria defined above is absent
  • Patient with acute coronary syndromes (ACS) requiring transfer to resuscitation unit and not to intensive care unit for any reason
  • Coronary angiography not performed or performed \> 24 h after first troponin assay in ICU
  • Pregnant or breastfeeding woman
  • Patient unable or refusing to sign inform consent
  • Patient without health care insurance
  • Patient under legal guardianship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

UH Nîmes

Nîmes, Gard, 30029, France

RECRUITING

UH Montpellier

Montpellier, 34295, France

RECRUITING

UH Toulouse

Toulouse, 31050, France

WITHDRAWN

Related Publications (3)

  • Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K; PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005 Aug 6-12;366(9484):472-7. doi: 10.1016/S0140-6736(05)67061-4.

    PMID: 16084255BACKGROUND
  • Bonnefoy-Cudraz E, Bueno H, Casella G, De Maria E, Fitzsimons D, Halvorsen S, Hassager C, Iakobishvili Z, Magdy A, Marandi T, Mimoso J, Parkhomenko A, Price S, Rokyta R, Roubille F, Serpytis P, Shimony A, Stepinska J, Tint D, Trendafilova E, Tubaro M, Vrints C, Walker D, Zahger D, Zima E, Zukermann R, Lettino M. Editor's Choice - Acute Cardiovascular Care Association Position Paper on Intensive Cardiovascular Care Units: An update on their definition, structure, organisation and function. Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):80-95. doi: 10.1177/2048872617724269. Epub 2017 Aug 17.

    PMID: 28816063BACKGROUND
  • Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575. No abstract available.

    PMID: 32860058BACKGROUND

MeSH Terms

Conditions

Non-ST Elevated Myocardial Infarction

Interventions

HospitalizationIntensive Care Units

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesHospital UnitsHealth Facilities

Central Study Contacts

Florence LECLERCQ, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2021

First Posted

December 10, 2021

Study Start

December 18, 2021

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

January 17, 2024

Record last verified: 2024-01

Locations